Good morning to all of you, and welcome to this year-end presentation for Benchmark. I am Trond Williksen, and as usual, I'm here together with our CFO, Septima Maguire, and we are going to take you through the financial and operational results for the full year, but also the last quarter of our financial year 2024. We are following the normal program, starting with the highlights, moving over to more granularity on the business areas. Septima will go through the financials in detail, before we end with sharing our view on the outlooks for the company, from where we stand today, in the quarters and the time that we have ahead. At the end, of course, there will be an opportunity for Q&A as usual. But start off with the headlines of the year. Financial year 2024 has been a special year for Benchmark. A year of considerable change in the business, a year where we have managed, but also now concluded a strategic review, and a year where we have experienced market headwinds for a significant part of our business in the root. Despite all of this, we have managed to stay resilient to deliver an outcome that has brought Benchmark forward, to a better position in the future. Given that we now have concluded the strategic review, let me start on commenting this. As you are aware of, the outcome of the comprehensive review that we have been through is that we have signed an irrevocable agreement to sell our genetics business to Novo Holdings. We firmly believe this is a good outcome of the review. First of all, we believe that the deal very well reflects the significant intrinsic value of the genetics business that we have been developing throughout the years. Then, the significant proceeds from the transaction also enable the company to pay down expensive debt, both the NOK bond that we have, but also the RCF, and to return significant capital back to our shareholders. Finally, the deal enables the company, on the basis of a solid financial footing, less complex, to focus on realizing the real values in the remaining part of the business, our advanced nutrition, and our health business areas. The process that we went through to get to the conclusion was comprehensive, and we received offers for all the three business areas, but also for the whole group. For the reasons I just mentioned, we are confident that the outcome of the review is good for the company and for our shareholders. The transaction is expected to close in the first quarter of calendar year 2025. Post closing of the transaction, Benchmark becomes a less complex company with a significant opportunity to further streamline the organization to reduce costs. Thus, it will be in a better position for value creation for our shareholders going forward. Before leaving this page, just a few reflections on the genetics business that we are now is being sold to Novo Holdings. This is a business that, during the period of the ownership of Benchmark, has been developed to become a considerable force, a leading player in aquaculture, in the aquaculture genetics space. From the beginning, this was also the intention. But going back to the starting point, and I think we go back to 2015, the starting point was small fraction businesses within the genetics areas that were gathered. And over the years, it has been invested in and developed to become a really significant and a coherent business. This is now also reflected in the significant value achieved through the transaction. This evidence value creation Benchmark has been able to generate over the years, an ability that is being applied and will be applied also for the remaining part of Benchmark going forward. Then moving over to talk about the highlights of the operational performance in financial year 2024. And I will refer to the group figures in totality. Septima, we will go through more in detail the continuing business in her part of the transaction. As I started out, financial year 2024 has been a year of considerable change, a year with market headwinds for a significant part of our business. Despite this, we have managed to stay resilient to deliver a result that reflects dynamic mitigation to the challenges that we have been facing throughout the year. The top line, for, for the whole group ended at GBP 147.7 million. This is a reduction of 7% in constant exchange rate compared to last financial year. If you look behind the top line, we see growth in the top line, in advanced nutrition, 5% in constant exchange rate, which we consider this as a strong performance given the significant market headwinds this business area has been facing in the shrimp market, which is their main market. And this has been a topic that I've addressed throughout the whole year, during our presentations. Revenues for health were down 41% compared to last year. This is also something that has been addressed throughout the year. It's explained by the considerable change and restructuring we did in this business area during the year, taking out the two PSV-based platforms for CleanTreat as a first and needed step towards a less capital-intensive business model for EctoSan Vet, our new medicine. Doing so, of course, implied far less top line for this business, but on the contrary, we have now positioned the business area to be profitable and cash-positive going forward. Finally, genetics, where we saw a reduction in revenues of 8% in constant exchange rate during the year, still reflective of a good year, but not a year where we benefited from the extraordinary uplift by supply constraints that we experienced back in financial year 2023, but also in 2022. But it's also reflective of the shift that I addressed, at least in two quarterly presentations before, the shift that we've seen from direct sales to more indirect sales during the joint venture we have with SalMar. Overall, Adjusted EBITDA, excluding fair value for the group as a whole, ended at GBP 28.9 million, which is down 10% in constant exchange rate compared to last year. This is, of course, explained by a reduction in top line that I just commented, but it's also explained by a reduction in gross margin due to changes in product mix for nutrition, which I will come back to and comment. Partly, the alternative has been mitigated by a significant reduction in operating cost throughout the year. It has been taken down 15% throughout the year. Unlike last year, but I think also unlike financial year 2022, this year ended with an operating loss for the group. We are, of course, not happy with that, but it's partly, of course, explained by the lower revenues and gross margin, but it should be noted that the figure is significantly impacted by impairments of a total of GBP 15.3 million, out of which the majority comes from an impairment of capitalized development cost related to EctoSan Vet and CleanTreat. It's reflecting a prudent approach, given that we have paused the commercial activities while we're working on tangible alternatives to relaunch a solution on a less capital intensive platform for this solution. Then moving over to talk on Q4, the last quarter of the year and how that has been developing for the group in total. Top line in the quarter ended at GBP 36.8 million, which is an increase of 7% in constant exchange rate compared to Q4 last year. Behind this group figure for the quarter, we see growth in top line for our advanced nutrition business, good performance given the market conditions, while we've seen a significant reduction in the revenues of health for the same reasons that I've just gone through. In genetics, we had a solid quarter with modest growth compared to last year. Our adjusted EBITDA, excluding fair value for the quarter, ended at GBP 6.9 million. It's a reduction from last year. As I will come back to in a minute, this reflects a growth, a lower gross margin due to the product mix in advanced nutrition, but it's also influenced by unfavorable movements in biological assets in genetics in the quarter. On the positive side, also here, if you look at this quarter, we see that the figures reflect our effort to mitigate through our reduction in operating costs, which has been down 35%, in this quarter compared to last year. Operating loss in the quarter. It's already been commented on. It's mainly driven by the impairments, a consequence of the prudent approach to capitalized development cost in health. Moving over to give a little bit more granularity on the two business areas that will remain in the group going forward, advanced nutrition and health, and starting out with advanced nutrition. That has shown great resilience, demonstrating commercial focus in what I will call difficult, very difficult market conditions throughout this year. As previously stated and gone through, that has led to an increase in top line, top line in this year, measured in constant exchange rate. And if you compare that to how we see other players in the market, I think it's, it's a strong performance. The challenge of, for this business, or for the business in advanced nutrition or INVE, which is the well-known brand, for this part of the group, besides being difficult market, in shrimp, has been the product mix. The challenging market situation in shrimp, in the shrimp industry has made it more difficult to sell the highest margin products in the portfolio due to increased price sensitivity of the customers. In addition to this, Artemia is a natural resource with fluctuation in hatching rate, which is the main quality parameter. And during the year, we've had a greater influx, or bigger influx of the inventory of Artemia with lower hatching rate, thus lower quality, thus lower margin. So that's the explanation. You can see it partly here that the health products, which is the high margin product, has gone down during the year, again, a result of the market situation that has impacted overall product mix during the year. When it comes to the Artemia part, this is a situation that we expect that we move out of, over the coming periods, as we are now moving into inventories of higher quality Artemia, from the last season's harvest. As I've stated in previous presentations over the last two years, we have had a strong focus on optimizing our performance in nutrition, regardless of the market situation that we have been in. Decisive actions have been taken to strengthen our commercial focus, broaden our commercial product range, and increase operational efficiency to mitigate the market cyclicality. Even if we are down in performance against last year, we are very confident that the performance that we show this year reflects these actions and demonstrates a strong ability to mitigate the situation that we have been in. A few words about the market situation, and this is a repetition of what I've said in previous presentations over the last at least two years. Good news is that the market in marine fish, which is mainly the sea bass, sea bass industry in the Mediterranean, has, from our perspective, stayed quite stable, and we have been able to perform rather well in that segment. The challenge has been, and it continues to be, the shrimp market that still is difficult with low farm grade prices to the farmers, which again affects their ability and willingness to stock and grow the production in various regions. This is a situation that has been close to two years now. We feel confident that this will turn over time. We know that there are cycles. When that happens is still uncertain. What we will do and what we have done is to continue focus on what we can do something with. We know that we have a very solid and tuned organization and management in Advanced Nutrition in INVE that has been strengthened during the last years. We know that we have a very good and wide product portfolio that is in continuous development, and we know that we have a very relevant footprint in the market that also has been widened and strengthened over the past years. With this in mind, we are confident that we are in a good position in the current state of the market, but also when the market again turns, to become more positive, and it will. Moving over to talk about the health business, which is the second business area which will remain in the group after the transaction. This is an area that has gone through a very significant change over the last year, which I've already commented on. It's of course, reflected in the financials. The restructure we have done as a first and needed step, to transition from a very capital-intensive business model for EctoSan Vet and CleanTreat has of course, impacted our top line and Adjusted EBITDA in the year that we have finished. At the same time, it has positioned the business area as a smaller but profitable and cash-positive business with the capabilities to grow going forward. The current backbone of this business area is the sea lice medicine Salmosan, Purisan that still is doing well in the market, as one of the very few medicines available for efficacious sea lice treatment in the salmon industry. But we have also kept our capability in this area to provide the EctoSan CleanTreat solution. Given the magnitude of the sea lice challenge for the Norwegian, but also the Chilean industry, there is still a significant potential in this solution. Interest is in the market, and we continue to work on, and as well as being in dialogue with customers and partners to get this solution live again. This on a platform, which will be less costly, less capital-intensive for Benchmark as well as for the customers, it being on the barge. I've also talked about, integrated into wellboat or land-based, a land-based setup for it. The latter being a solution that will significantly reduce cost as everything is less costly if you bring it to a land-based platform. So with these comments on the business areas, I will leave it up to you, Septima, to take us through more in detail when it comes to the financials. Thank you, Trond. The floor is yours. As noted, given where we are in the context of the divestment, I'm going to focus on talking to the continuing business, as it is most relevant as we move forward into the future. But when we look at financial year 2024, what is the continued business? The continued business in the financial year 2024, from an accounting and reporting perspective, is the total business less the perimeter of the transaction of the divestment. What has happened is we are divesting of our genetics business. Within that genetics business during the year, we would have had infrastructure within the corporate cost section to support that business. But of course, that remains with the continued business. The cost that we would have allocated into that business of GBP 1.9 million remain with the continued business. And the perimeter of what will be in the discontinued operations from an Adjusted EBITDA perspective is GBP 16.7 million. When you look at the financial year 2024 from a continued business, but also from a future perspective, what will the future look like? The future will look like the nutrition business, as Trond highlighted, the health business, and the corporate costs of financial year 2024 will not reflect the going forward corporate costs because the business will be supporting two smaller, less complex business areas. As such, what we see in our financial year 2024 figures is reflective of the reality of financial year 2024, but not the future. I am going to take you through the figures. From a revenue point of view, when we look at the revenue, and particularly in terms of the most significant remaining part of the continued business, nutrition, Trond referenced the year as a resilient year. It definitely has been. The focus within the nutrition business has been, even with the difficult end markets that we were experiencing, for the commercial teams to create more sales opportunities. That has actually been proven as we have grown at a constant exchange rate our nutrition revenue by 5%. When we look at our health business, Trond also referenced the fact that we have reduced down this revenue by 41% at a constant exchange rate, but that's due to the exit of EctoSan and CleanTreat out of the market. When we look at the remaining business from a health perspective, Salmosan and Purisan, it contributed GBP 7.8 million of revenue to the financial year 2024 result, which is a good sales and profit, profit-generating part of the business. When we look at the gross profit for the nutrition business, we did experience gross profit fall due to the fact that we were selling Artemia, which had a lower hatching rate during the year. This resulted in a drop of 11% at a constant exchange rate. It must be remembered, nutrition delivered gross profit in the year of GBP 36.7 million. It is a profitable business even when we are experiencing challenges within the market. When we look at health, whilst we did see a drop of gross profit from health through the exit of EctoSan out of the market, we have to remember why we did this. We exited EctoSan out of the market so that we could mitigate the cash burning cost of the platform supply vehicles out of our cash burn to ultimately create a cash-generative business. So what we're left with now from a gross profit perspective is the Purisan business and the future possibilities of EctoSan. But from a Purisan perspective, this delivered GBP 5.8 million of gross profit within the continued business for financial year 2024. We expect this to be an important part of the cash generation for the future of the business. Now, I'm going to look at the R&D and the operating costs in one of the later slides. But the one point I would make is that the focus this year has been on mitigating the lost margin. Whilst we haven't fully achieved it, we have done well in terms of achieving Adjusted EBITDA of GBP 11.9 million for the continued business. You also must consider that that also includes the GBP 1.9 million of costs, which would have normally been allocated to genetics. Trond noted that the adjusted operating profit or loss includes the impairments that we experienced from an EctoSan and CleanTreat perspective. Those impairments were driven by the fact that we could not predict the timings of the cash flows for the future of that business model. We were trying to be prudent as we approached the future for Benchmark as a whole. When we look at the exceptional costs, GBP 4.5 million of that relates to exceptional costs associated with the strategic review, and the balance of it relates to restructuring associated with, mainly the health business area. Net finance costs I'll look at in a few minutes as well, because I think it's an important point to look at how the business will be structured, how the income statement will be structured for the future. But as you can see, when you look at the loss before tax and after tax, we have experienced a significant increase. It's based on trading challenges, the impairments, high finance costs, which will go away, high operating exceptional costs, which will go away. Ultimately, we are pivoting as we move to the future. Moving on to the next slide to look at operating costs. When we look at the operating costs, first of all, you can see in the continued business, we have put in a significant amount of effort to mitigate the costs. And as you can see, the reduction of GBP 7 million is significant year on year in the continued business. Now, GBP 3.5 million of that relates to the fact that no bonuses were paid in this financial year, which is reflective of the fact that we, when we win as a business, our employees win. When our business struggles, our employees are with us on this. But also you can reflect on the fact that the rest of it actually is due to good cost constraints within the continued business, and that's within nutrition, within health, and within the corporate business areas. Looking at the R&D investment, we've continued to invest in mainly nutrition as we are committed to the future portfolio development within this business area. And in terms of the capitalized R&D, you can see it's reduced because we ceased some of the initiatives within the health business area as part of the restructuring activities of health. So then moving on to the net financial expenses. So I'm going to go down this line by line and talk about what is changing. So when we look at the net financial expenses and we look at the foreign exchange losses and gains, every business is exposed to foreign exchange gains and losses. But from a continued business, the nutrition business mainly trades in dollars. So there is an element of natural hedging within that. The health business has some foreign exchange exposure related to the Norwegian krone and the US dollar, but it's not significant, so the foreign exchange profile becomes a lot clearer, then when I look at the interest on the bond and the bank debt, now we've stated our intention is to repay the bond and the RCF, and of course, given the fact that the divestment deal itself is on a cash-free, debt-free basis, the seller loan will also fall away as part of the divestment, so the intent around this line is for it to be much more moderate as we have deleveraged the business, which is part of the intention of this transaction. The amortization of deferred finance fees, if I don't have big debt, I don't have big deferred financing, so ultimately that falls away. Similarly, hedging, as we will be repaying the knock bond, the hedging associated with that will also fall away. And it will make for a much simpler profile for this. And then in terms of the lease interest, as you can see, this is a much more moderate level of lease interest. And this purely relates to lease interest on the remaining business. The main sites that are within this are one of the manufacturing sites that we have in nutrition in the U.S. But ultimately, financial expenses hopefully will become much more moderate and much simpler. Then when we look at the cash flow, again, it's quite a discussion about where does everything go now. When I look at my cash generated from operations, all of this is actually based on the total business. We can. We have not been able to split it out into just continued business. So but what I will focus on is what will fall away. So when I look at my working capital, we had a significant investment in working capital in the year. But what is within that that will fall away? Well, within the year, we had GBP 2.2 million of movements in payments in the provisions for the decommissioning of the PSV [vessels] in health. That won't reoccur. We also had the movement in working capital associated with the genetics business of GBP 4.8 million. Again, that goes away with the divested business. We will, of course, have normal trading activity. There is always ebbs and flows from a working capital point of view, particularly when we have lumpy working capital profiles in some of our businesses. From a tax point of view, again, as I've previously stated, we pay tax in our tax-paying jurisdictions of Belgium, Norway, and Iceland mainly, but when we look at the payments for the year within that GBP 6.8 million, there is tax paid. Sorry, there's a significant tax paid associated with the genetics business area within that. Moving to look at CapEx of GBP 3.9 million, GBP 2.2 million of that related to the genetics business area, and the balance was GBP 0.1 million related to health with the balance related to CapEx associated with our production facilities in the U.S. and Thailand for within nutrition. Then again, when we look at the interest, because of the fact that we won't have any bonds, we won't have the RCF, they'll have been repaid, the interest payment becomes much more moderate and actually will only be reflective of the lease interest that we're paying associated with our properties. So when we look at the business, what will it look like from a practical point of view? The purpose of the transaction is to deleverage the business, to give the business the ability to generate cash and use that cash within the business or to return capital to the shareholders. And, in terms of the actual divestment proceeds, the intent is, with the proceeds to repay the debt and use the proceeds to return, as Trond noted, a significant return of capital to shareholders, to reflect the shareholder value that has been created over the last number of years. But ultimately, we feel that through this transaction and this pivot for Benchmark, we create a much more financially viable operation and a much stronger, cleaner balance sheet so that we can move forward into the future. So I'm going to pass you back to Trond. Thank you, Septima. Let's move on to talk about from where we are right now, how are we moving forward. As I stated initially, we think that and I think that's evidenced also with what Septima has just gone through, we think that the outcome of the strategic review is good, not only because we believe that the sale of genetics fully reflects the intrinsic value the genetics business has that has been developed over the years, but also because it will put the group on a good footing with a solid balance sheet, with a leaner, less complex organization, streamlined, less costly, and with an ability to focus on realizing the value that we have in the two remaining business areas. And the potential in those business areas are definitely there. Both businesses are now positioned to be cash positive, profitable. They have leading positions in what they are doing. They have an invested infrastructure. They have good, solid organizations and a headroom to grow. That creates a good opportunity to realize more values for our shareholders. And the focus will be exactly that. Strategically, both businesses are well defined. Advanced Nutrition is a highly specialized nutrition and health business focusing on solutions for the early life stages. So far, targeting the global shrimp and marine fish markets. Advanced Nutrition or INVE represent a unique, very well invested platform within this space with an excellent solution portfolio, solid supply chain infrastructure, impressive commercial organization covering all the relevant markets, as well as a very solid and experienced management. As an organization and as a business, INVE has developed strongly over the last years, which is evidenced by the resilience shown in the, especially in the last two years, where we have been tested with very, very challenging market conditions. Where we are now, the business in sum is very well positioned for when the market again turns, as well as to expand to reach an even wider part of the aquaculture industry. Still staying very true to the core of the strategy of Advanced Nutrition or INVE, being a highly specialized business with a highly specialized portfolio commanding high margins in what we are doing. Health is through the decisive steps that I've repeated twice already in my presentation so far. It's now emerging as a lean, profitable, and cash-generating business, with a solid financial platform created by the business that is developed with our established business in Salmosan and Purisan that is still doing very well. But health, as I've already said, has a significant bigger potential than that through EctoSan Vet and CleanTreat, where we have kept our capabilities and keep on working on alternative platforms and through dialogue with customers will that will enable a relaunch of this solution. These will be platforms that are far less capital intensive than the solutions involving the PSVs that we use for the introduction of the solution. And I've previously been speaking about models integrated in wellboats or barges, but also land-based models. And these platforms will be owned and operated by customers. Benchmark provides the medicine and holds the financial potential in the medicine of EctoSan Vet, which is what we are supposed to do. For anybody who is doubting the need of EctoSan Vet and CleanTreat as part of the tool in the sea lice treatment, in the salmon industry, I would just point to the situation of sea lice, over the last fall, how it has been in Norway. It's been the sea lice issue has been worse than ever. And the situation is not better in other regions. In Chile, where we have a lack of tools that really work, there the situation has really put the industry into new tests during the last year. So the need of the solution into the toolbox is definitely there. So, then over to speak, a few words about how we look at this in a more, you know, short term. I'm talking about the first quarter of this financial year that we have entered into now, financial year 2025, but also the year for the two business areas. For nutrition, the start of the year has seen a continuation of the challenging trading conditions that we have seen in the shrimp market, in financial year 2024. It's still the situation. Post-period, we have also experienced a loss of a significant customer in Venezuela, as you should all know. The political situation in that country is unstable, and the government in the country has taken control over the operation of this particular customer, so despite that, the business area continues to do well given the market conditions. It continues to deliver a very resilient performance. We expect a soft Q1. During the year, we expect a recovery in the gross margin, which has been one of the issues that we've been facing throughout this, not this last year, which was caused by the product mix, and in part by the nature of previous Artemia harvest. We are also confident that the actions taken over the past years to strengthen our commercial effort, broaden our product portfolio, and increase our operational efficiency, to mitigate the impact of market cyclicality, will position us to deliver growth and improve profitability in the period to come. In health, we have had, I would say, a very good start of the year with the new setup of the business. Salmosan, EctoSan Vet and Purisan is selling well in the market. It's well positioned in the customer's tool kits to tackle sea lice. So we have seen a very good development of that in the beginning of the year. And with the reduced cost base for our health business, it will, it is positioned to be profitable and cash positive going forward. At the same time, as I've already repeated many times, we continue to work on viable models and are in dialogue with customers on EctoSan Vet and CleanTreat, with the aim to relaunch this solution into the market. For the group as a whole, we will focus, focus will be on streamlining and simplifying the group structure, which will, which will lead to a significant cost savings. This effort will commence upon completion of the disposal of genetics, also taking into consideration that the company has a commitment under a Transition Services Agreement with Novo. We aim to complete that in three months after the closing of the deal. So we expect that the streamlining exercise will be complete at the end of Q3 in our financial year, and that we will see the real benefit of the work that is ahead of us on that to come through in Q4 and into financial year 2026. So with these words on the outlooks, I, I think we end our presentation, and we are opening up for questions. Thank you. All right. Thank you. Just checking first to see if there are any questions in the room. Yep. One moment. Hey, Alex Sorokin from DB. You say you want to pay down all the debt, but going forward, will you be having a more normalized debt level, one times EBITDA, 1.5? Any comments on that? And also, is it possible to give any indications of your long-term margin targets under the new structure? I'll take that one. Yeah, you can take that one. The objective is to effectively be a deleveraged business, but to have flexible debt facilities in place to support the normal ebb and flow of the business. Longer-term, leverage targets aren't something that we've really delved into. What we're trying to do is we're trying to make sure that the business is well placed, strong balance sheet, strong facilities to move forward into the next phase of its development. From a margin perspective, in terms of the actual individual business areas, in terms of the previously guided targets around long-term margins for nutrition, those, those would be what the businesses would be pushing back towards. Nutrition will always work towards those margins, and we will always, as a management team, do everything we can to help support them as well. In terms of Salmosan and EctoSan, Salmosan, the margins are, as we've previously noted, quite strong in terms of the product, albeit it is a smaller product, and as we can bring EctoSan back to the market, that will help strengthen that margin profile, but then the next piece, of course, which is something that we're working on in the future, will be taking away the margin drag from corporate costs, and so that's not fully evolved from this, at this point in time. Great. Any other questions in the room? Okay. Moving on to the online questions. As part of the strategic review, was it always the priority to dispose of genetics? I think we went into it quite, we didn't have any firm saying, "We're going to do this," you know? I think we went into it quite open-ended. And that was the way that the process was designed. And as I said, you know, we received offers on all the three business areas, but also the group in totality. And then the considerations the board did and we did during the process ended up that, you know, let's get to the best solution. And the best solution was what we have ended up in the disposal of genetics, keeping the two business areas in order to develop further values out of those. Great. And you've already touched on this, but the question reads, are there, after the transaction, what are your priorities moving forward? The priorities is to make sure that we know our, you know, on one side, we just want to focus very strongly to keep the momentum and the development of the two remaining business areas. Of course, in parallel with that, we need to close the transaction and all this technical thing around that. And then, of course, our focus will be to, to enter into a process where we are streamlining, the organization, according to the new setup that Benchmark will have, you know? We are remained with two business areas. It's obvious that we need to do something with, with the setup in order to, to that to be, you know, fit for purpose. So that is, of course, the, the focus that we have, now in order to get that done. As I said, we have planned to get that done now and to complete that when we are, when we have completed the, the transaction, but also we are out of the TSA that we have with Novo delivering that in. And we expect to see a final result of that during Q3 in our financial year 2024, which is Q2 in the calendar year. Yeah. Great. And post-transaction, what will be the species distribution for the group? The species, you know, it will be less salmon than it has been since salmon is a significant part of the genetics business. I think shrimp will be probably the market that we are most present in. A wide range of marine fish because it's yes the backbone of the marine fish business that we're doing is sea bass, sea bream in the Mediterranean, but we are also into a range of marine fish throughout the world. But it will be the same distribution, but less salmon. We will do salmon, of course, related to Salmosan, Purisan, and also EctoSan Vet going forward, but less than we have done previously. Thank you. And financially, moving forward, what changes can we expect to see in terms of how the business will be run more efficiently? Well, as I said, you know, the focus now will be on making sure that the operations are optimized and we get enough focus on the two remaining business areas so we keep the momentum in developing those going forward to run those as efficient as possible. Then, as I also said, it's about streamlining the group, taking out cost, making it fit for purpose that will affect a lower cost structure, so the focus will be to run it as efficient as possible going forward. That is what we have done through this strategic review. We have come to a conclusion which enables us to run the two remaining business areas even more efficient than we have done so far. There's been a reference to a significant payout to shareholders. Yep. Can you indicate a range for the expected dividend? Septima, you can answer that. We can't at this point in time, but if you consider the fact that we have referenced in the RNS when we announced the transaction, the gross proceeds, and we have already stated the intention around repaying the debt, you can gain an order of magnitude from doing the math around that. But until we actually have completed the transaction and have gone through those completion metrics, we won't be able to nail that number. But I think that it's something that it's been really important in terms of this whole process to return value to shareholders. Shareholders have stood with us all through the last five years and all through the journey of Benchmark. And that is a consideration as we've made choices as a board. You know, we don't give an exact number now, and we need to come back to that, you know, but when we are seeing a significant return of capital to the shareholder, that's, we mean that. Great. Unless there are any other questions in the room, that concludes the Q&A session. Thank you. Okay. Then that concludes the year-end presentation for Benchmark. So thank you for attending for those who are in the venue and those who are listening in. Thank you.